Clinomics is committed to prevent diseases

About Us

Clinomics Europe is a Budapest-based company, established in 2021 June.

The innovative field of the healthcare sector has become more and more crucial during the world crisis caused by the pandemic. Our high added-value, rapidly growing medical biotech company pays special attention to helping patients by developing novel precision diagnostic devices and methods.

Our core technology is based on an early-stage cancer diagnosis by genetic analysis of circulating tumor cells. The unique method allows us to prolong the life of cancer patients. For early-stage cancer diagnosis, a unique technology such as liquid biopsy is essential. Liquid biopsy can confirm the presence of cancer through the separation and determination of cancer cells present in the blood. NGS (Next-Generation Sequencing) test is a technology used to obtain necessary data to diagnose diseases by analyzing the genetic information. Using the liquid biopsy method in combination with NGS-based cancer panel, it is possible to improve the quality of life by providing precise medical treatment to cancer patients. This combined solution of high-end technologies such as liquid biopsy, bioinformatics, NGS takes personalized medicine to a never-seen high level.

Innovation in molecular diagnostics

We focus on research and development of innovative molecular diagnostic methods performed by the most recent high-end technologies, such as liquid biopsy, next-generation sequencing, qPCR etc.

Sales and Tech Support

In addition to our R&D and clinical service activity, our company represents itself by professional sales and product specialists. Our goal is to build an international business network and provide the highest quality support to our partners and customers.